These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7737903

  • 1. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
    Sasaki Y, Mizuno S, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K, Sekine I, Miyata Y, Saijo N.
    Jpn J Cancer Res; 1995 Jan; 86(1):117-23. PubMed ID: 7737903
    [Abstract] [Full Text] [Related]

  • 2. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG.
    Cancer Chemother Pharmacol; 1995 Jan; 36(6):463-72. PubMed ID: 7554037
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K.
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [Abstract] [Full Text] [Related]

  • 4. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
    Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N.
    Jpn J Cancer Res; 1995 Jan; 86(1):101-10. PubMed ID: 7737901
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of CPT-11 in rhesus monkeys.
    Inaba M, Ohnishi Y, Ishii H, Tanioka Y, Yoshida Y, Sudoh K, Hakusui H, Mizuno N, Ito K, Sugiyama Y.
    Cancer Chemother Pharmacol; 1998 Jan; 41(2):103-8. PubMed ID: 9443622
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC.
    Cancer Res; 1994 Jan 15; 54(2):427-36. PubMed ID: 8275479
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX, Hu ZP, Chan SY, Duan W, Ho PC, Boelsterli UA, Ng KY, Chan E, Bian JS, Chen YZ, Huang M, Zhou SF.
    Curr Drug Metab; 2006 May 15; 7(4):431-55. PubMed ID: 16724931
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A.
    J Clin Oncol; 1996 Oct 15; 14(10):2688-95. PubMed ID: 8874328
    [Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R.
    Ann Oncol; 1995 Feb 15; 6(2):141-51. PubMed ID: 7786822
    [Abstract] [Full Text] [Related]

  • 14. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
    Sloan JA, Atherton P, Reid J, Pitot HC, Erlichman C, Schaaf L.
    Cancer Chemother Pharmacol; 2001 Sep 15; 48(3):241-9. PubMed ID: 11592347
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 15; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO.
    J Clin Oncol; 2002 Aug 01; 20(15):3293-301. PubMed ID: 12149304
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients.
    Barilero I, Gandia D, Armand JP, Mathieu-Boué A, Ré M, Gouyette A, Chabot GG.
    J Chromatogr; 1992 Mar 27; 575(2):275-80. PubMed ID: 1629304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.